The Affordable Care Act (aka, Obamacare) is perhaps the signature piece of legacy legislation in President Obama's nearly completed two terms in the White House. In these cities, the uninsured rates are lowest.
Shares of Summit Therapeutics more than doubled on Tuesday after it was announced that it would be entering into a licensing deal with Sarepta Therapeutics.
24/7 Wall St. has collected several big FDA decisions and mid-stage to late-stage trials that should be announced in October.
Jaguar Animal Health Inc. (NASDAQ: JAGX) filed a Form S-1 with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering. The expected price of the 4.32 million shares is $1.20 per share. The…
Over the past week, a few biotech companies made absolutely massive runs. The companies 24/7 Wall St. has picked stood out from the rest with at least 25% gains.
The SEC has charged the former senior director of regulatory affairs for Puma Biotechnology with insider trading ahead of the company’s news announcements about its drug to treat breast cancer.
Any of these three top pharmaceutical companies makes an outstanding addition to more conservative portfolios. They are also far less volatile and act better than biotechs if the market gets dicey.
Catabasis Pharmaceuticals shares skyrocketed on Thursday following an announcement that it would be partnering with Sarepta Therapeutics for a joint research collaboration.
If there is one trend that has worked in America, it is the trend of betting on the public taking care of their pets. Now Merrill Lynch has issued a report on the state…
Alcobra saw its shares get halved on Thursday after the U.S. Food and Drug Administration (FDA) placed a clinical hold on its late-stage trial.
Mylan just has been unable to recover from its EpiPen pricing hike issue. Thursday's additional weakness was tied to a late Wednesday report from U.S. federal health regulators.
Shares of Genocea Biosciences saw a handy gain early on Thursday on positive news from its genital herpes trial, but investor enthusiasm was short lived.
Intra-Cellular Therapies saw its shares absolutely crash on Thursday following the results from its late-stage schizophrenia trial.
Shares of Anavex Life Sciences soared on Wednesday following a material transfer agreement with Biogen.
In a Jefferies research report, the top growth stock picks for this week are littered with outstanding biotech companies that could be poised for some big moves.
